Chikungunya Virus Antibody

Eligibility Details: Inclusion Criteria: - Male or female ≥ 18 and ≤ 50 years of age - Weight of 50 to 100 kg, inclusive - In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening - Has access to consistent and reliable means of contact and agrees to stay in contact with the study site for the duration of the study Exclusion Criteria: - Any acute or chronic clinically significant disease, as determined by physical examination or laboratory screening tests - Elevated liver function tests or safety laboratory test results - Positive screening test for the presence of anti-CHIKV IgG - Administration of another investigational study involving any investigational product within 60 days or 5 half-lives, whichever is longer - Has received any live attenuated or inactive vaccines within 4 weeks prior to check-in, or plans to receive any vaccine during the study - Known or suspected immune-mediated disease or immunosuppressive condition (including lymphoproliferative disorders) - Any neurologic disorder - History of idiopathic urticaria - Any bleeding disorder that is considered a contraindication to study drug infusion or blood collection - Receipt of immunoglobulins, a monoclonal antibody or any blood products within the preceding 6 months - Any acute illness at the time of enrollment - A positive test result for drugs of abuse - A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2 antibodies - A history of active cancer (malignancy) in the last 3 years - Donation of ≥ 450 mL blood or blood products within 30 days of study drug infusion